Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Recombinant Human Interleukin-11 (rhIL-11)
Recombinant Human Interleukin-11 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Recombinant Human Interleukin-11 (rhIL-11) | DRUG | - |
Inclusion Criteria: * Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed. * Men and women age 16 years and over. * Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
Recombinant Human Interleukin-11 is an investigational biologic developed by Pfizer, Inc. (PFE) for Crohn disease. It is also known as rhIL-11. It is a Phase 2 candidate in the gastrointestinal therapeutic area and has been studied in a completed Phase 2 trial in patients with active Crohn disease and inflammatory bowel disease.
Recombinant Human Interleukin-11 has been studied for the treatment of active Crohn disease, a form of inflammatory bowel disease. It is an investigational agent and is not an approved therapy for Crohn disease. Its clinical evaluation was conducted in a Phase 2 study in the United States.
Recombinant Human Interleukin-11 is an exogenous protein, and its molecular target is F9. It is classified as a small molecule modality in the available drug record. The target class is described as an exogenous protein, reflecting that the agent is a recombinant protein rather than a conventional small molecule therapeutic.
Recombinant Human Interleukin-11 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the clinical evaluation of the agent in Crohn disease. The drug is also referred to as rhIL-11.
Recombinant Human Interleukin-11 is in Phase 2 development. It is investigational and has not been approved for any indication. One Phase 2 trial has been completed, and no trials are currently active. The completed study was randomized and double blind.
Recombinant Human Interleukin-11 was evaluated in the Phase 2 study NCT00040521, titled Study Evaluating rhIL-11 in Active Crohn's Disease. The trial enrolled patients with Crohn disease and inflammatory bowel disease in the United States, included participants aged 16 years and older, and has been completed.